Laboratory Tests for Juvenile Idiopathic Arthritis
For children with suspected JIA, order the following core laboratory panel: complete blood count (CBC), erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP), rheumatoid factor (RF), anti-cyclic citrullinated peptide (anti-CCP) antibodies, antinuclear antibodies (ANA), and HLA-B27 (if enthesitis-related arthritis is suspected). 1, 2
Essential Laboratory Tests
Inflammatory Markers
- ESR and/or CRP: Both should be obtained in all suspected JIA cases. Elevated ESR is present in 98% of systemic JIA (sJIA) cases, and elevated CRP (>6 mg/L) is found in 97-99% of cases 1. These markers are critical for establishing the presence of inflammation and monitoring disease activity.
Complete Blood Count
- CBC with differential: Essential for all JIA evaluations 1, 2
- Leukocytosis (>15,000/mm³) occurs in approximately 52% of sJIA cases
- Anemia (Hb <12 g/dL) is present in 89% of sJIA patients
- Thrombocytopenia is a critical red flag: Platelets <100×10⁹/L have a pooled odds ratio of 108.4 for acute lymphoblastic leukemia versus JIA 3. If thrombocytopenia is present with neutropenia or anemia, bone marrow aspiration must be performed immediately to exclude malignancy before starting any immunosuppressive therapy.
Autoantibodies and Serologic Markers
- Rheumatoid factor (RF): Identifies RF-positive polyarticular JIA, which represents a distinct disease entity with worse prognosis 4, 5
- Anti-CCP antibodies: Should be ordered alongside RF, as both define risk factors for more aggressive disease requiring earlier biologic therapy 4
- Antinuclear antibodies (ANA): Particularly important for identifying early-onset ANA-positive JIA and assessing uveitis risk 5
- HLA-B27: Order when enthesitis-related arthritis or sacroiliitis is suspected clinically 4
Organ Function Tests
- Liver function tests (LFTs): Elevated transaminases occur in sJIA and are essential baseline measurements before starting DMARDs 1, 6
- Renal function tests: Baseline creatinine and urinalysis 6
Systemic JIA-Specific Testing
For suspected systemic JIA, add:
- Ferritin level: Markedly elevated ferritin (>1120 ng/mL) has 74.5% sensitivity and 94.1% specificity for distinguishing sJIA/AOSD from sepsis 1
- Glycosylated ferritin fraction: If available, ≤20% has 79.5% sensitivity and 66.4% specificity for sJIA/AOSD 1
- Lactate dehydrogenase (LDH): Elevated in sJIA and helps differentiate from malignancy 3
Critical Diagnostic Pitfalls
Exclude Malignancy First
Never initiate corticosteroids or immunosuppressive therapy until malignancy is excluded 3, 7. The triad of thrombocytopenia, neutropenia, and anemia has extremely high diagnostic weight for acute lymphoblastic leukemia (pooled ORs >100 for each) 3. Additional red flags include:
- Nocturnal bone pain disproportionate to physical findings
- Hepatosplenomegaly
- Markedly elevated LDH
- Weight loss
Macrophage Activation Syndrome Monitoring
In established sJIA, monitor for MAS with:
- Ferritin levels (extremely elevated, often >10,000 ng/mL)
- Ferritin-to-ESR ratio (high sensitivity and specificity for MAS versus infection) 1
- Declining platelet counts, fibrinogen
- Elevated triglycerides, transaminases
Tests That Are NOT Diagnostic Screens
Do not use these tests as rheumatological "screens" 8:
- ANA, RF, and HLA-B27 have poor positive predictive value when ordered without specific clinical suspicion
- Order these only when clinical features suggest a particular JIA subtype
- No single laboratory test is diagnostic of JIA—diagnosis remains clinical with laboratory support
Monitoring During Treatment
Once treatment is initiated 6, 9:
- Methotrexate: CBC, LFTs, and renal function within 1-2 months, then every 3-4 months
- Sulfasalazine/Leflunomide: Same monitoring schedule as methotrexate
- NSAIDs: CBC, LFTs, renal function every 6-12 months
- TNF inhibitors: CBC and LFTs annually
- Tocilizumab: CBC and LFTs within 1-2 months, then every 3-4 months; lipid panel every 6 months
Additional Considerations
The median delay from initial sJIA diagnosis to correct alternative diagnosis can be 9.5 months in misdiagnosed cases 7. Maintain high vigilance for atypical features and perform dynamic reassessment, as sJIA is a diagnosis of exclusion requiring ongoing evaluation to distinguish it from autoinflammatory diseases, vasculitis, and malignancies.